Table 1.
Summary of recently developed vaccine candidates.
| Vaccine Platform | Manufacturer | Type of Antigen | Dose of antigen | Adjuvant | Delivery Platform | Dosing Regimen | Route of administration | Storage Temperature | CITATION |
|---|---|---|---|---|---|---|---|---|---|
| mRNA-1273 (Spikevax) | Moderna | Nucleoside mRNA encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus | 100 ug | Lipid particles | 2 doses of 0.5 ml each 1 month apart | IM | -50°C to -15°C | https://www.fda.gov/media/155675/download | |
| BNT162b2 (Comirnaty) (Purple cap: To be diluted; Gray cap: Not to be diluted; some excipients differ) | Pfizer/BioNTech | Nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2 | 30 ug | Lipid particles | 2 doses of 0.3 ml each 3 weeks apart | IM | -90°C to -60°C | https://www.fda.gov/media/151707/download; https://www.fda.gov/media/154834/download | |
| JNJ-78436735 (Ad26.CoV2.S) | Janssen | Replication-incompetent recombinant adenovirus type 26 (Ad26) vector expressing the SARS-CoV-2 spike (S) protein in a stabilized conformation |
5 × 10^10 virus particles | Viral vector | one dose of 0.5 ml | IM | 2°C to 8°C | https://www.fda.gov/media/146304/download | |
| ChAdOx1-S (Vaxzevria) | Oxford (Mfd by AstraZeneca) | Chimpanzee Adenovirus encoding the SARS-CoV-2 Spike glycoprotein ChAdOx1-S | 2.5 × 10^8 infectious units | Viral vector | 2 doses of 0.5 ml each 4 to 12 weeks apart | IM | 2°C to 8°C | https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf | |
| Covishield | Oxford (Mfd by Serum Institute of India) | Chimpanzee Adenovirus encoding the SARS-CoV-2 Spike glycoprotein ChAdOx1-S | 5 × 10^10 virus particles | Viral vector | 2 doses of 0.5 ml each 4 to 12 weeks apart | IM | 2°C to 8°C | https://www.seruminstitute.com/pdf/covishield_ChAdOx1_nCoV19_corona_virus_vaccine_insert.pdf | |
| Covaxin | Bharat Biotech | Whole-virion inactivated SARSCoV-2 antigen (Strain: NIV-2020-770) | 6 ug | 250 ug aluminum hydroxide gel, 15 ug TLR 7/8 agonist (imidazoquinolinone) | - | 2 doses of 0.5 ml each 4 weeks apart | IM | 2°C to 8°C | https://www.bharatbiotech.com/images/covaxin/covaxin-pack-insert.pdf |
| NVX-CoV2373 (Nuvaxovid) | Novavax (Biological active subtances mfd by Serum Institute of India) | SARS-CoV-2 spike protein | 5 ug | Matrix-M: Fraction-A (42.5 ug) and Fraction-C (7.5 ug) of Quillaja saponaria Molina extract | - | 2 doses of 0.5 ml each 3 weeks apart | IM | 2°C to 8°C | https://www.ema.europa.eu/en/documents/product-information/nuvaxovid-epar-product-information_en.pdf |
| BBIBP-CorV (Covilo) | Sinopharm (Beijing) | Inactivated antigen of SARS-CoV-2 WIV04 strain | 200 WU | Aluminium hydroxide | - | 2 doses of 0.5 ml each 3-4 weeks apart | IM | 2°C to 8°C | https://www.fda.gov.ph/wp-content/uploads/2021/08/Product-Information-of-SinoPharm-Covid-19-Vaccine-Covilo.pdf |
| CoronaVac | Sinovac | Inactivated SARS-CoV-2 CZ02 strain | 600 SU | Aluminium hydroxide | - | 2 doses of 0.5 ml each 4 weeks apart | IM | 2°C to 8°C | https://www.covidvaccine.gov.hk/pdf/CoronaVac_ENG_PI_brief.pdf |
| Sputnik V (Gam-COVID-Vac) | Gamaleya National Research Center (different mfr in different countries) | Component I contains Recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene | 1.0±0.5 × 10^11 Particles | - | Viral vector | first component I at a dose of 0.5 ml, then after 3 weeks component II at a dose of 0.5 ml. | IM | -18°C or below | https://www.fda.gov.ph/wp-content/uploads/2021/03/12.-Proposed-Philippine-package-insert-Instruction-Eng.pdf |
| Component II contains Recombinant adenovirus serotype 5 particles containing the SARS-CoV-2 protein S gene | 1.0±0.5 × 10^11 Particles | ||||||||
| Sputnik Light | Gamaleya National Research Center (different mfr in different countries) | Component I contains Recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene | 1.0±0.5 × 10^11 Particles | Viral vector | Single dose of 0.5 ml | IM | -18°C or below | https://sputnikvaccine.com/about-vaccine/sputnik-light/ |